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Abstract 27 
Diabetes is the major cause of end stage renal disease globally, and novel 28 
treatments are urgently needed. Current therapeutic approaches for diabetic 29 
nephropathy are focusing on the inhibition of the renin angiotensin aldosterone 30 
system, on glycaemic and lipid control, and life style changes. In this review we will 31 
highlight new molecular insights in our understanding of the initiation and 32 
progression of diabetic nephropathy including glomerular insulin resistance, 33 
dysregulation of cellular substrate utilisation, podocyte-endothelial communication 34 
and inhibition of tubular sodium coupled glucose reabsorption. We believe these 35 
mechanisms offer new therapeutic targets that can be exploited to develop important 36 
renoprotective treatments for diabetic nephropathy over the next decade.  37 
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INTRODUCTION 39 
Diabetes mellitus is a metabolic disorder associated with chronic micro- and 40 
macrovascular complications. One of the most feared chronic microvascular 41 
complications is diabetic nephropathy (DN), currently the leading cause of end-stage 42 
renal disease (ESRD) in the Western world. Strikingly, 40-45% of patients with type-43 
1 diabetes (T1D) develop DN and reach ESRD or die before its onset. Moreover, 44 
clinicians face a ~30% prevalence of patients with type-2 diabetes (T2D) and DN, 45 
with 45% of patients currently on dialysis having a primary diagnosis of diabetes, a 46 
population also at high risk of developing cardiovascular disease [1]. 47 
 48 
An early sign of DN is an increased amount of urinary protein, manifested by 49 
“albuminuria”, which correlates with, and can predict, the progression of renal 50 
damage. Albuminuria arises from defects in the permeability of the glomerular 51 
filtration barrier consisting of glomerular endothelial cells (GECs) separated from 52 
specialized epithelia, called podocytes, by the glomerular basement membrane 53 
(GBM)[1]. Podocytes have extensive inter-digitating foot processes connected 54 
together by a slit diaphragm composed of proteins including nephrin and neph1, 55 
which interact with cytoplasmic adaptor and signalling proteins (PI3-Kinase, CD2AP, 56 
AKT, podocin). Nephrin is also linked with the podocyte actin cytoskeleton; the 57 
protein tyrosine kinase Fyn promotes nephrin phosphorylation which enhances its 58 
interaction with PI3-Kinase and PI3K-dependent phosphorylation of AKT and 59 
subsequently increases Rac1 activity, leading to modification of the actin 60 
cytoskeleton with maintenance of a normal podocyte anatomical structure and 61 
function [2, 3]. The structure and integrity of the glomerulus is also maintained by a 62 
complex local autocrine/paracrine network between the podocyte and the GECs 63 
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consisting of vascular growth factors and vasoactive peptides which is disrupted in 64 
DN [4]. The GECs are highly fenestrated with a unique ultrastructure lacking 65 
fenestrae diaphragms which facilitate water and small solutes permeability [5]. GECs 66 
are covered by a glycocalyx consisting mainly of proteoglycans which include core 67 
proteins such as syndecan and attached glycosaminoglycan side chains which 68 
appear to be important in regulating the permeability of the glomerulus [6]. 69 
 70 
Animal and human studies have established that the metabolic and haemodynamic 71 
changes that occur in diabetes lead to ultrastructural alterations of the glomerular 72 
filtration barrier, including podocyte foot process fusion and detachment, GBM 73 
thickening, a reduced endothelial cell glycocalyx, mesangial extracellular matrix 74 
accumulation and glomerulosclerosis (Figure 1). These structural glomerular 75 
changes correlate with increasing albuminuria which has been proposed to be a 76 
marker of generalised systemic vascular dysfunction by the “Steno hypothesis” [7] 77 
and could represent a common pathogenetic mechanism for renal and extra-renal 78 
chronic vascular complications in diabetes [1]. 79 
 80 
Over the last 5-10 years our understanding of the molecular and cellular pathways 81 
by which diabetic kidney disease results in damage to the glomerular filtration barrier 82 
has increased. In this review, we will outline recent advances in glomerular insulin 83 
signalling, oxidative and endoplasmic reticulum (ER) stress and podocyte-endothelial 84 
communication that have revealed new exciting therapeutic directions for DN. 85 
 86 
 87 
Insulin resistance as a mechanism for the predisposition of DN 88 
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Insulin is a metabolic hormone which not only regulates glucose and the metabolism 89 
of other substrates but also directly modulates the biology of specific cells in a 90 
variety of tissues. In both T1D and T2D patients, the ability of insulin to elicit cellular 91 
responses is impaired, a concept termed “cellular insulin resistance”, and is 92 
associated with DN [8]. Insulin resistance correlates with the development of 93 
microalbuminuria both in T1D and T2D patients and patients with T1D are more 94 
likely to have a strong family history of insulin resistance when compared with those 95 
without kidney disease [9]. Insulin resistance has been implicated in the 96 
development of glomerular hypertension and hyperfiltration [10], seen in the initial 97 
phase of diabetic kidney disease [11]. Furthermore, in both T1D and T2D patients, 98 
insulin resistance per se contributes to higher salt sensitivity, which closely associates 99 
with increases in blood pressure, albuminuria, and a decline in renal function [12, 13]. 100 
 101 
Within the kidney many different cell types are insulin sensitive and express functional 102 
insulin receptors [14-17]. Furthermore, transgenic mouse models have revealed that 103 
inducing insulin resistance in different nephron compartments results in a variety of 104 
unfavourable renal phenotypes. In the glomerulus, approximately a decade ago it 105 
was discovered that human podocytes respond to insulin [14], and express the 106 
hallmark components of insulin sensitive cells including the insulin receptor, and key 107 
glucose transporters including GLUT4 and GLUT1. To elucidate the biological 108 
significance of insulin signalling in these cells, podocyte specific insulin receptor 109 
knockout mice were generated [18]. These animals developed albuminuria and a 110 
number of features of DN, including increased matrix production, glomerulosclerosis, 111 
and GBM thickening, but all in normoglycaemic conditions, suggesting that insulin 112 
resistance of this cell per se may be an important driver in glomerular diseases. 113 
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Insulin signaling is important in other parts of the nephron. Deletion of the insulin 114 
receptor In tubular epithelial cells widespread led to reduced natriuresis and 115 
hypertension [16]. Recent studies have begun to dissect out the precise function of 116 
the insulin receptor in specific tubular segments. These experiments revealed that 117 
loss of the insulin receptor in proximal tubules results in gluconeogenesis [19] while 118 
deletion in collecting ducts increased natriuresis and lowered blood pressure [20].  119 
 120 
 121 
Diabetes provides an ideal environment consisting of increased adiposity, 122 
hyperglycaemia, and inflammation which are all important players in promoting 123 
podocyte insulin resistance and glomerular dysfunction [17](Table 1). A recent study 124 
has identified SMAD3 within the inflammation/ fibrosis pathway as an important 125 
modulator of podocyte insulin sensitivity in a model of obesity related DN [21]. In this 126 
work, mice fed a high fat diet exhibited an increase in kidney and podocyte SMAD3 127 
expression levels which resulted in a severely fibrotic kidney; in these conditions 128 
SMAD3 knockout animals were protected from kidney damage and fibrosis. In 129 
parallel, fatty acid palmitate induces a SMAD3-mediated podocyte insulin resistance 130 
paralleled by mitochondrial dysfunction in vitro. These responses were exaggerated 131 
when animals became albuminuric, and could be rescued by SMAD3 blockade and 132 
restoration of podocyte insulin signalling [21]. Other studies have demonstrated that 133 
both Nucleotide-binding oligomerization domain containing protein 2 (NOD2)[22] and 134 
Toll-like receptor (TLR)[23] mediated-inflammation have an adverse effect on 135 
podocyte survival, insulin action, and glomerular permeability to protein. Decreased 136 
circulating adiponectin [24, 25], increased free fatty acids (FFA) levels  [26], and 137 
defects in insulin action promote glomerular cells and podocyte dysfunction, and 138 
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albuminuria [27, 28]. Epigenetic mechanisms may also be important in determining 139 
insulin resistance [29]. This concept has not been studied in great detail to-date, but 140 
Kumar and colleagues have shown that insulin resistance induced by palmitate in 141 
human urinary podocyte cell lines is associated with an increase in histone 142 
H3K36me2 and reduced H3K27me3 on the promoter region of FOXO1, a regulator 143 
of gluconeogenic genes. This effect was long-lasting and persisted even after the 144 
normalisation of palmitate levels [30]. 145 
 146 
 147 
Glomerular insulin resistance, endoplasmic reticulum (ER) stress and 148 
autophagy in diabetic glomerulopathy 149 
There are many consequences of insulin resistance within glomeruli, which are likely 150 
to contribute to the progression of DN. One key mechanism is changes to the 151 
mitochondria and the closely connected ER [31]. Mitochondrial metabolic overload 152 
results in increased cellular oxidative stress and ER-stress which leads to the 153 
activation of unfolded protein response (UPR)[32]. UPR is a positive cellular 154 
response that in its early phase either refolds accumulated unfolded proteins, or 155 
degrades unfolded protein by the ubiquitin-proteasome pathway. Misfolded proteins 156 
are detected by the ER membrane stress sensors protein kinase RNA-like ER kinase 157 
(PERK), inositol-requiring protein 1α (IRE1α) and activating transcription factor 6α 158 
(ATF6α) and its activator X-box binding protein-1 (XBP-1), which, in turn, activates 159 
several signalling events and trigger a compensatory response to prevent further 160 
accumulation of misfolded protein. However, when the unfolded protein and cellular 161 
damage exceeds a threshold, chronic and unresolved stress results in a change 162 
from an adaptive to pro-apoptotic responses [32]. 163 
 8 
 164 
There is some evidence that glucose/oxidative stress-mediated ER stress plays a 165 
role in chronic vascular complications in DN [33]. Hyperglycemia, or increased 166 
glycation of proteins have been shown to mediate apoptosis partly through increases 167 
in ER stress in cultured murine podocytes [34, 35]. Activation of the UPR has also 168 
been observed in mouse glomerular mesangial cells exposed to glucose and 169 
glucosamine [36], and in kidneys from diabetic rats administered streptozotocin for 170 
16 weeks [37]. Microarray analysis of human biopsies from patients with established 171 
DN showed that UPR genes were upregulated proportionally to the severity of 172 
diabetic renal lesions [38]. Finally, recent experimental evidence has demonstrated 173 
that pharmacological inhibition of ER stress and stabilization of the UPR is beneficial 174 
in diabetic glomerulopathy [39]. 175 
 176 
Two studies have used transgenic mice to link podocyte insulin resistance with 177 
mitochondrial function and ER stress. Ising and colleagues generated a mouse 178 
model of podocyte mitochondrial dysfunction by specifically knocking out a key 179 
molecule in this cell involved in mitochondrial fusion called prohibitin-2 [40]. This 180 
caused a severe phenotype including glomerulosclerosis, renal failure and death at 181 
approximately a month of age. They then went on to inhibit both the insulin receptor 182 
and IGF-1 receptor (IGF1R) contemporaneously with podocyte-specific knockdown 183 
of prohibitin-2. Inhibiting the insulin receptor alone, or in combination with the IGF1R 184 
was partially protective and resulted in a significantly longer life span of the mice 185 
[40]. This suggests that insulin resistance could reflect a “protective” resetting of 186 
cellular substrate utilisation to shield from excess substrate flow to mitochondria with 187 
“impaired” respiratory capabilities. In another study, Madhusudhan et al. have 188 
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elegantly shown that under diabetic conditions ER adaptive mechanisms are 189 
impaired in the podocyte and that this is exacerbated when the cell is rendered more 190 
insulin resistant. Studying human and murine DN they discovered that nephropathy 191 
was associated with alterations in the UPR with impairment of the nuclear 192 
translocation of XBP-1. Genetic ablation of the transcription factor XBP-1 or 193 
activation of ATF6 (downstream of XBP-1) in the podocyte of diabetic mice 194 
aggravates DN. Of interest, mice with genetically impaired podocyte insulin signalling 195 
exhibited impaired UPR (XBP-1 activation) that was associated with more severe 196 
diabetic kidney disease when compared with diabetic controls [41]. 197 
 198 
Autophagy, regulated by the mammalian target of rapamycin complex 1 (mTORC1) 199 
is, with the UPR, essential to maintain cellular homeostasis and in the context of ER 200 
stress contributes towards the elimination of toxic and damaged cellular components 201 
[42]. Haploinsufficiency of mTORC1 in podocytes or administration of rapamycin (a 202 
mTORC1 inhibitor) resulting in activation of autophagy [43], has been shown to 203 
prevent progressive DN [44, 45]. In contrast, mTORC1 activation in podocytes, 204 
resulting in inhibition of autophagy, leads to accelerated DN [46]. Loss of insulin 205 
sensitivity in cultured podocytes results in suppression of autophagy and addition of 206 
rapamycin in these cells attenuates insulin resistance [47]. 207 
 208 
 209 
Insulin resistance, the glomerular cell cytoskeleton and other mechanisms 210 
Experiments using podocyte cell lines have begun to reveal other downstream 211 
targets of insulin resistance which may play a role in DN. Addition of exogenous 212 
insulin to human podocytes in culture led to cytoskeletal rearrangement [18], a 213 
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process which has been pharmacologically targeted using small molecules as a 214 
novel therapy for DN [48]. Other studies [49] have identified the cytoskeleton protein 215 
septin-7 as playing an important role in the regulation of insulin-mediated 216 
translocation of GLUT4 vesicles to the plasma membrane and the control of 217 
podocyte glucose transport. Insulin may also modulate calcium signalling in 218 
podocytes which has been shown to be important in maintaining cytoskeletal 219 
dynamics by altering the expression of canonical transient receptor potential-6 220 
channel-TRPC6 [50] and large-conductance Ca(2+)-activated K(+) channels [51].  221 
 222 
Insulin stimulates the Phosphoinositide 3-kinase (PI3K) pathway and causes AKT 223 
activation. In normal physiology, insulin stimulation of podocytes results in AKT 224 
phosphorylation (activation), while, in insulin-resistant disease settings such as 225 
diabetes, a number of reports have shown an early loss of glomerular AKT 226 
phosphorylation whilst AKT signaling is maintained in the tubular compartment of the 227 
kidney [28].  AKT exists in three isoforms with AKT2 being located specifically in the 228 
podocyte within the kidney [52]. A loss of podocyte AKT2 activation is detrimental 229 
when there is chronic kidney disease associated with nephron loss [52]. AKT2 is the 230 
major isoform through which insulin signals [53]. It is currently not completely clear if 231 
the loss of renal AKT activation is detrimental in the setting of diabetes as a number 232 
of studies have shown an increase in AKT phosphorylation in the vasculature in 233 
experimental animal models of diabetes [54-58], and pharmacological inhibition of 234 
the AKT activation by AS101, may confer renoprotection in diabetes [59]. More work 235 
will have to be performed to dissect the exact role of AKT in diabetic kidney disease. 236 
 237 
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Insulin can also modulate the renin-angiotensin-aldosterone system, critical for 238 
regulating glomerular haemodynamics in DN, by increasing the expression and 239 
activity of angiotensin converting enzyme-2 (ACE2)[60]. Further work is required to 240 
identify other downstream targets of podocyte insulin signalling ideally using systems 241 
biology genomic and proteomic approaches. Candidate molecules altered by insulin 242 
signalling might include recently identified genes found to be associated with the 243 
early stages of albuminuria in in-bred strains of mice [61]. 244 
 245 
 246 
Reactive oxygen species and diabetic nephropathy 247 
Over the last decade, an attractive unifying hypothesis has been put forward to 248 
explain diabetic microvascular complications; specifically it was postulated that an 249 
excess in cellular substrate availability leads to an increase in reactive oxygen 250 
species (ROS) which in turn drives vascular complications in DN [62]. However, this 251 
unifying hypothesis has been challenged by the negative results of antioxidant-based 252 
clinical trials [63], and a new theory of “mitochondrial hormesis” has been proposed 253 
[64], whereby the increased mitochondrial superoxide production is considered an 254 
indicator of healthy mitochondria and physiologic oxidative phosphorylation. 255 
 256 
Recent research has found a reduction of superoxide in the kidneys of streptozotocin 257 
(STZ)-induced diabetic Akita-mice, as assessed by a combination of in vivo real-time 258 
transcutaneous fluorescence, confocal microscopy, and electron paramagnetic 259 
resonance analysis [65]. The authors of this study found that chronic exposure to 260 
high glucose levels (as occurs in diabetes) results in disrupted mitochondria, which 261 
was associated with a reduced respiration and a lowering in mitochondrial 262 
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superoxide. Interestingly, genetic or pharmacological correction of mitochondrial 263 
dysfunction by improving substrate utilisation was recently found to be renoprotective 264 
in a mouse model of tubulointerstitial fibrosis [66].  265 
 266 
From experimental animal studies it appears that increased cytosolic superoxide and 267 
other non-mitochondrial sources of ROS generation play a prominent role in diabetic 268 
kidney disease and that strategies involving a more targeted (towards specific cellular 269 
compartments such as the cytosol) antioxidant approach, may be important to 270 
optimize renoprotection in diabetes [67]. Along these lines, human studies have 271 
shown that leukocytes obtained from patients with diabetes and DN (when compared 272 
with non-diabetics or patients with diabetes without DN) have a reduced maximal 273 
respiration and reserve capacity [68, 69] suggesting that chronic metabolic stress in 274 
the presence of a reduced mitochondrial function (being this primary or secondary) 275 
will manifest with low ATP-linked respiration, low reserve capacity and reduced 276 
mitochondrial ROS generation. 277 
 278 
It could be speculated that metabolic stress could initially (early phase) promote an 279 
excess production of mitochondrial superoxide [62] that will lead, in a subsequent 280 
chronic phase (late phase), towards mitochondrial damage, progressive deterioration 281 
in bioenergetic cellular function, reduced ATP synthesis and cell death. Future work 282 
will address these questions, and need to evaluate whether cells are able to maintain 283 
adequate number of healthy mitochondria which can then burn sufficient substrates 284 
for energy production and maintain a “balanced” level of ROS (Figure 2). 285 
 286 
 13 
AMP-activated protein kinase (AMPK) is a stress-activated kinase that is activated in 287 
response to depleting ATP to preserve cell survival under conditions of reduced 288 
substrate utilisation. AMPK activation has been involved in mitochondrial biogenesis 289 
by leading to increased mitochondrial substrate utilisation and ATP generation, in 290 
parallel with stimulation of antioxidant gene expression to ensure an optimal redox 291 
balance [70]. Reduced AMPK, as seen in the diabetic kidney of both rodents and 292 
humans [65], is associated with reduced catabolic activity (mitochondrial function) 293 
[65], and reduced AMPK-mediated inhibition of NADPH oxidase (Nox2) resulting in 294 
increased ROS production [71, 72]. Taken together, these results suggest that, in the 295 
diabetic kidney, upregulation of AMPK could be therapeutically beneficial in DN [73] 296 
to regulate nutrient utilisation and mitochondrial function towards maintenance of an 297 
optimum redox balance. 298 
 299 
Overall, more work is required in the DN field to dissect between these opposing 300 
theories specifically by examining mitochondrial function and specific ROS moieties 301 
both in vitro and in tissues. 302 
 303 
 304 
Vascular endothelial growth factor-A (VEGFA) and the glycocalyx 305 
Recent studies have shown a connection between insulin resistance and the 306 
subsequent production of VEGFA in podocytes [74]. This finding is likely to be 307 
important in the setting of DN with many elegant studies using transgenic mice 308 
highlighting the importance of podocyte VEGFA levels in the progression of this 309 
condition [4]. A new aspect of VEGFA signalling in the glomerulus is potential cross 310 
talk between VEGFA secreted from podocytes and the GECs glycocalyx in the 311 
 14 
setting of diabetes. There is clear evidence that the GECs glycocalyx is lost both 312 
systemically and within the diabetic glomerulus, and that this contributes to both 313 
cardiovascular and renal complications [6]. Mechanistically there are a number of 314 
pathways which led to loss of the glomerular glycocalyx including hyperglycaemia 315 
[75], and ROS [76].  316 
 317 
During the early phases of diabetes an increase in VEGFA causes glycocalyx 318 
shedding from the GECs. Furthermore, the inhibitory isoform of VEGFA called 319 
VEGF-A165b also plays a role in maintaining the GECs glycocalyx in diabetes. Oltean 320 
et al. [77] have shown that in diabetic patients with progressive nephropathy, the 321 
renal expression of VEGF-A165b is lost. They went on to develop a number of murine 322 
models of DN and have shown that genetic overexpression or pharmacological 323 
administration of VEGF-A165b to the mouse, acting through VEGF receptor 2 in the 324 
GECs, restores damaged glomerular endothelial glycocalyx and improves renal 325 
function. VEGF-A165b also improved the permeability of isolated human diabetic 326 
glomeruli suggesting the response is conserved across murine and human species 327 
[77]. 328 
 329 
VEGFA signalling is only one component of a complex system of molecular cross 330 
talk between the podocyte and glycocalyx. New insights have revealed that 331 
molecules produced by the endothelium can signal to the podocyte and then back to 332 
the glomerular glycocalyx. Using transgenic murine models and conditionally 333 
immortalised murine podocytes and GECs, Garsen et al have shown that endothelin-334 
1 (ET-1), an endothelial derived vasoconstrictor, is released by the GECs in diabetic 335 
conditions and leads to shedding of the glycocalyx [78]. This is prevented by deleting 336 
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the ET-1 receptor specifically in the podocyte. This is therapeutically intriguing as 337 
there are ET-1 receptor antagonists that have been shown to ameliorate early 338 
microalbuminuric diabetic kidney disease [79]. In the future, therapeutic approaches 339 
to maintain the GECs glycocalyx should be explored in more detail (Figure 3). 340 
 341 
 342 
SGLT2 and kidney disease 343 
Poor glycaemic control and hyperinsulinaemia (at least in the early phase of diabetes) 344 
lead to upregulation of SGLT2 expression and proximal tubular SGLT2-mediated 345 
sodium-glucose reabsorption [80], which in turns is believed to also contribute to 346 
higher blood pressure levels [81]. SGLT2 inhibitors have recently been developed as 347 
oral hypoglycaemic agents [82]. The SGLT2 antagonists block the sodium-coupled 348 
energy dependent glucose proximal tubular reabsorption resulting in improvement in 349 
diabetes control, weight loss and blood pressure lowering. Recent clinical trials have 350 
demonstrated a dramatic cardiovascular [83] and renoprotective [84] effect of the 351 
SGLT2 inhibitor empaglifozin. 352 
The mechanism by which SGLT2 inhibitors exert their renoprotective effects is 353 
currently unknown. One possibility is that the improvement in renal disease is 354 
secondary to activation of tubuloglomerular feedback, a prime mechanism that 355 
determines a reduction in glomerular capillary pressure [85]. A complementary 356 
mechanism may be that the inhibition of enhanced tubuli sodium-coupled glucose 357 
transport seen in diabetes would result in diminished tubulointerstitial injury and 358 
progression of DN [81]. The use of SGLT2 inhibitors in combination with inhibitors of 359 
the renin-angiotensin-aldosterone system in patients with diabetes may confer some 360 
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renoprotection via upregulation of ACE2 and angiotensin 1-7/ 1-9 [86] which retains a 361 
vasodilatory, anti-proliferative, anti-inflammatory and anti-oxidative stress effect [87].  362 
Inhibition of SGLT2 increased expression and activity in diabetes [85] could lead to 363 
restriction of chronic excess in substrates (glucose) availability, known to result in 364 
AMPK inhibition [88], and promote a favourable renal outcome. Studies wll have to 365 
dissect whether inhibition of SGLT2 could result in AMPK activation and secondary 366 
renoprotection.  367 
In parallel to these “renal mechanisms”, natriuresis and plasma volume contraction 368 
paralleled by blood pressure reduction has been also been proposed as a “systemic” 369 
renoprotective mechanisms for SGLT2 inhibitors [89](Figure 4). 370 
 371 
Concluding Remarks and Future Perspectives  372 
Glomerular cellular insulin resistance plays an important role in mitochondrial 373 
dysfunction-ER stress and the UPR, which contribute to glomerular cell dysfunction 374 
and progressive kidney disease. AMPK, with its important role in mitochondrial 375 
function, could represent a potential target for treatment in DN; more studies are 376 
required to assess the role of AMPK on podocyte biology and the regulation of the 377 
glomerular filtration barrier. A link between the tubular compartment and the 378 
glomerulus is evident in the pathophysiology of tubular SGLT2-mediated Na-coupled 379 
glucose reabsorption in diabetes, however it is not yet completely clear what are the 380 
mechanisms underlying these beneficial effects. Future studies will need to better 381 
dissect the cellular mechanisms underlying the proposed pathways outlined in this 382 
article, specifically focusing on the physiology of the nephron as a whole entity, and 383 
by identifying potentially targetable molecules for future treatment.   384 
 385 
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TABLE 1  400 
Diabetes results in inflammation, increased adiposity and chronic hyperglycaemia 401 
which drive podocyte insulin resistance resulting in disruption to podocytes and the 402 
glomerulus.  (NOD2: Nucleotide-binding oligomerization domain containing protein 2, 403 
TLR: Toll-like receptor, SMAD: vertebrate homologues of Sma and Mad; FFAs: free 404 
fatty acids; SHP-1: Src homology-2 domain-containing phos- phatase-1) 405 
 406 
Diabetes related 
phenotypes 
Molecular 
mechanisms 
Glomerular phenotype REF # 
Chronic 
inflammation 
Increased NOD2 
Increased pro-
inflammatory responses 
and impaired insulin 
signaling 
 [22] 
Increased TLR 
Podocyte inflammation 
and insulin resistance  
  [23] 
Increased SMAD 
Mitochondrial 
dysfunction and insulin 
resistance in podocytes 
    [21] 
Obesity 
Decreased 
adiponectin 
Albuminuria and 
increased oxidative 
stress in podocytes 
    [24] 
Increased FFAs 
Inhibition of insulin-
stimulated glucose 
uptake in human 
podocytes 
    [26] 
Elevated blood 
sugar 
Increased SHP-1 
Podocyte insulin 
resistance and 
detachment 
     [27] 
Ubiquitination and 
degradation of 
components of insulin 
signaling pathway  
Diabetic glomerulopathy 
and albuminuria 
     [28] 
 407 
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Figure legends: 408 
 409 
Figure 1: Schematic structure of a normal and diabetic glomeruli.  410 
(A) Schematic representation of a normal glomerular structure. (B) The major 411 
glomerular structural changes occurring in diabetic glomerulopathy. Note the 412 
extensive mesangial expansion, the thickening of the glomerular basement 413 
membrane (GBM), the detachment of podocyte, and the impairment in the 414 
glycocalyx and glomerular endothelial cells (GECs). 415 
 416 
Figure 2: Hypothetical shift of superoxide level imbalance in diabetic 417 
complications. 418 
Acute (early phase) exposure of cells to elevated glucose levels results in 419 
upregulation of glucose oxidation with pyruvate-mediated stimulation of the 420 
tricarboxylic acid (TCA) cycle with increased production of electron donors (NADH, 421 
FADH2) that, via the electron transport chain, will results in an excess generation of 422 
superoxide (O2-). Cells chronically exposed to elevated glucose levels (late phase) 423 
will result in reduction in the availability of acetyl-CoA (secondary to inhibition of 424 
pyruvate dehydrogenase activity) for the mitochondria resulting in reduced electron 425 
transport chain activity, a fall in mitochondrial ATP production, less mitochondria 426 
superoxide production and cellular dysfunction. 427 
 428 
Figure 3: Glomerular cell cross-talk and glycocalyx.  429 
Transmission electron microscopy image of the glomerular filtration barrier (podocyte 430 
glomerular basement membrane (GBM), glomerular endothelial cells (GEC), and 431 
glycocalyx) highlighting how molecules produced by the podocytes and endothelium 432 
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(via the podocyte) can signal to the glomerular glycocalyx. Recently identified key 433 
molecules such as VEGF-A165b, VEGF-C, and angiopoietin-1 (ANGPT1) confer a 434 
beneficial effect (green arrows) towards glycocalyx maintenance. Conversely VEGF-435 
A165 and Endothelin (secreted by GECs and signals to the Endothelin-1 receptor in 436 
the podocyte causing this cell to release heparanase, which then acts on the 437 
glomerular glycocalyx to cleave heparin sulphate) promote shedding of the GECs 438 
glycocalyx (red arrows).  439 
 440 
Figure 4: Proposed SGLT2 inhibition-mediated renoprotective mechanisms. 441 
SGLT2 inhibition blocks sodium-glucose coupled glucose reabsorption at the S1 S2 442 
segment of the proximal tubule. The net result is loss of glucose and sodium (the 443 
latter especially in patients on renin angiotensin aldosterone blockade) in the urine, 444 
with secondary weight loss, improvement in glycaemic control, blood pressure fall, 445 
and plasma volume contraction. These effects confer cardiac and renal protection in 446 
patients with diabetes. (ACE2: angiotensin converting enzyme 2) 447 
  448 
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OUTSTANDING QUESTIONS BOX 658 
- What are the main pathway/s that link insulin action, mitochondrial function 659 
and UPR? 660 
- What are the mitochondrial-driven mechanisms that predispose towards faster 661 
kidney disease progression in diabetes? Is there an alteration in the mitochondria 662 
driven UPR-mediated response towards cell survival or is it a primary alteration in 663 
UPR response?  664 
- Does AMPK, with its important role as a regulator of nutrient utilisation and 665 
mitochondrial function, represent a real answer to diabetes mediated ER-stress 666 
mitochondria dysfunction, UPR, and, if so, what are the mechanisms? 667 
- Could targeting the glycocalyx be a new therapeutic approach for diabetic 668 
nephropathy? What are the important molecular signals from the podocyte and 669 
endothelium which regulate the glycocalyx? 670 
- How does SGLT2 inhibition confer reno-protection? Is it about SGLT2-driven 671 
sodium and volume loss (systemic effect) or tubuloglomerular feedback and 672 
inflammation (intrarenal effect)? Are these mechanisms behind the renoprotective 673 
effects of these drugs?  674 
 32 
TRENDS BOX: 675 
- Insulin resistance is a key mechanism for diabetic glomerulopathy. 676 
- Disruption in the molecular communication between glomerular podocytes 677 
and endothelia is critical in the progression of diabetic nephropathy. 678 
- Raised (but not too elevated) mitochondrial superoxide cellular levels in 679 
parallel with healthy mitochondria are protective against progression of 680 
diabetic kidney disease. 681 
- A reduction in maximal mitochondrial respiration and reserve capacity could 682 
represent an important driving force for kidney disease progression in 683 
diabetes. 684 
- Inhibition of SGLT2-mediated sodium-coupled glucose transport confers 685 
renoprotection of similar magnitude of inhibitors of the renin-angiotensin-686 
aldosterone system. 687 
  688 
 33 
Figure 1 689 
 690 
  691 
 34 
Figure 2 692 
 693 
  694 
 35 
Figure 3 695 
 696 
  697 
 36 
Figure 4 698 
 699 
 700 
